SCHEMBL24190146

SCHEMBL24190146

COC(=O)c1cc2c(C(F)(F)F)cccc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.46
SRC P12931 2/20 0.46
KIF11 P52732 2/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
CYP1A2 P05177 1/20 0.43
NR4A2 P43354 2/20 0.42
FLT3 P36888 2/20 0.42
ULK1 O75385 1/20 0.42
XDH P47989 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CBLB Q13191 1/20 0.41
NOTUM Q6P988 1/20 0.41
NR3C1 P04150 1/20 0.41
ALOX5 P09917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30396884 1.00 ABL1 (0.46) ABL1SRCKIF11GLAGAA
SCHEMBL30310641 0.85 KDM4E (0.51) GLAGAAKDM4EMEN1ALDH1A1
SCHEMBL700154 0.85 KDM4E (0.51) GLAGAAKDM4EMEN1ALDH1A1
SCHEMBL24740345 0.82 MEN1 (0.51) KDM4EMEN1KMT2ACBLB
SCHEMBL429658 0.82 GLA (0.46) ABL1SRCGLAGAACYP1A2
SCHEMBL30310417 0.82 KDM4E (0.53) KIF11GLAGAACYP1A2FLT3
SCHEMBL1144458 0.82 KDM4E (0.53) KIF11GLAGAACYP1A2FLT3
SCHEMBL2323348 0.81 FLT3 (0.59) KIF11GLAGAACYP1A2NR4A2
SCHEMBL19332486 0.81 NOTUM (0.43) ABL1SRCKIF11CYP1A2NR4A2
SCHEMBL31158902 0.81 FLT3 (0.49) GLAGAACYP1A2FLT3ULK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952365-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-09 US disclosed
CN-116096714-A Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections 安力高医药股份有限公司 2023-05-09 CN disclosed
US-20220009903-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-01-13 US disclosed
US-20220009903-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11952365-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 ABL1 483/4885SRC 2254/4885KIF11 1802/4885
US-20220009903-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 ABL1 483/4885SRC 2254/4885KIF11 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.